2020.08.31
I-Mab today announced financial results for the six months ended June 30, 2020 and provided an overview of recent highlights and upcoming milestones.
2020.08.17
I-Mab today announced that the first patient has been dosed with plonmarlimab (TJM2) in a Phase 1b study to evaluate its use in treating patients with rheumatoid arthritis in China.
2020.08.06
Conference Call Scheduled for August 31 at 8:00 a.m. ET with Pre-Registration Required.
2020.08.04
I-Mab today announced that the China National Medical Products Administration (NMPA) has accepted its pivotal trial application for eftansomatropin (also known as TJ101) as a weekly treatment for growth hormone deficiency in pediatric patients (PGHD).
2020.07.28
I-Mab today announced the appointment of Mr. Ivan Yifei Zhu as its Chief Commercial Officer, effective August 10, 2020. Mr. Zhu will report directly to Dr. Jingwu Zang, Founder, Honorary Chairman and Director of I-Mab. In this role, Mr. Zhu will focus on building and developing I-Mab’s commercializa...
2020.07.15
I-Mab announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to US$20 million of its ordinary shares in the form of American depositary shares.
2020.06.12
I-Mab and ABL Bio will be presenting preclinical data for joint bispecific antibody program at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020. The preclinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-M...
2020.05.29
I-Mab announced its participation in the following conferences in June, including Jefferies 2020 Virtual Healthcare Conference, Goldman Sachs Virtual Healthcare Corp Day, 2020 AstraZeneca China Healthcare Ecosystem Summit &3rd Commercial Innovation Partnership Conference and Institutional Capital Ad...
2020.05.28
I-Mab today announced interim results from a multi-center, double blinded, randomized, placebo-controlled, three-arm clinical study (NCT04341116) of TJM2 in patients with cytokine release syndrome (CRS) associated with severe coronavirus disease 2019 (COVID-19). This study adopts a robust clinical t...
2020.05.21
Two companies expand collaboration for development of TJ107/HyLeukin-7™. I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in China.